Free tool
FAERS Monitor: Tosymra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210884 or its brand name (Tosymra, Sumatriptan). Reports on generic versions are filed under their own applications.
Reports
18,395
Serious
11,313
62% of reports
Hospitalization
3,856
Death reported
585
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,839
- headache1,501
- migraine1,273
- nausea1,260
- fatigue1,073
- dizziness887
- pain851
- off label use838
- vomiting720
- dyspnoea658
- diarrhoea648
- anxiety613
- arthralgia502
- depression498
- malaise495
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 16 |
| 2005 | 12 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 20 |
| 2009 | 46 |
| 2010 | 83 |
| 2011 | 100 |
| 2012 | 334 |
| 2013 | 371 |
| 2014 | 554 |
| 2015 | 790 |
| 2016 | 1,137 |
| 2017 | 1,168 |
| 2018 | 1,728 |
| 2019 | 1,878 |
| 2020 | 1,637 |
| 2021 | 1,524 |
| 2022 | 1,432 |
| 2023 | 1,642 |
| 2024 | 1,340 |
| 2025 | 1,445 |
| 2026 | 1,132 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,764 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| migraineSignal | 1,273 | 15.4 | 14.6 | 17,025 |
| headacheSignal | 1,501 | 2.7 | 2.6 | 1,706 |
| depressionSignal | 498 | 2.5 | 2.3 | 453 |
| anxietySignal | 613 | 2.5 | 2.3 | 539 |
| dizzinessSignal | 887 | 2.0 | 1.9 | 477 |
| nausea | 1,260 | 1.8 | 1.7 | 484 |
| vomiting | 720 | 1.8 | 1.6 | 237 |
| drug ineffective | 1,839 | 1.6 | 1.5 | 436 |
| pain | 851 | 1.6 | 1.5 | 188 |
| fatigue | 1,073 | 1.6 | 1.5 | 234 |
| arthralgia | 502 | 1.4 | 1.3 | 53 |
| dyspnoea | 658 | 1.3 | 1.2 | 55 |
| malaise | 495 | 1.3 | 1.2 | 33 |
| diarrhoea | 648 | 1.1 | 1.1 | 13 |
| off label use | 838 | 1.1 | 1.0 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.